Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

NEW YORK, NY, December 16, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer’s disease.  The randomized trial is designed to assess the safety and exploratory…